Actualidad Menarini

Busca noticias de Menarini-CA

XII Simposium Centroamericano y del Caribe de Actualización en Atención Primaria

Donación Universidad Da Vinci Guatemala

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

III Simposium Centroamericano y del Caribe de Neurociencias

Protección y reparación de los tejidos de la mucosa bucal, ácido hialurónico de origen biotecnológico

Simposium Panamericano de Medicina del Deporte

«
1 de 25
«